BJMO - volume 13, issue 5, august 2019
P. Specenier MD, PhD
ASCO 2019 hosted several important presentations on Squamous Cell Carcinoma of the Head and Neck (HNSCC). Data on early stage and locally advanced HNSCC as well as recurrent/metastatic HNSCC were discussed.
Read moreBJMO - volume 13, issue 5, august 2019
T. Feys MBA, MSc, P. Vuylsteke MD
The highlights in gynecologic cancers from ASCO 2019 include data on the outcome of chemotherapy or PARP inhibitors as monotherapy or combination therapy in (elderly) patients with ovarian cancer, as well as results of immune checkpoint blockade in patients with advanced or recurrent endometrial cancer with or without a mismatch repair deficiency. Novel findings in (early-stage) cervical cancer include the efficacy and safety of neoadjuvant chemotherapy followed by surgery vs. chemoradiation, and of minimally invasive hysterectomy compared to open radical hysterectomy.
Read moreBJMO - volume 13, issue 5, august 2019
M. Peeters MD, PhD, H. Prenen MD, PhD
At ASCO 2019, several clinical trials regarding upper and lower gastro-intestinal tumors were presented.
Read moreBJMO - volume 13, issue 5, august 2019
J. Vansteenkiste MD, PhD, E. Wauters MD
In this article, the ten key messages with respect to thoracic oncology presented at ASCO 2019, are summarized.
Read moreBJMO - volume 13, issue 5, august 2019
M.J. Piccart-Gebhart MD
At ASCO 2019, many presentations featured recent progress in the breast cancer field. A lot of attention went to biomarkers but also the treatment of triple negative breast cancer, luminal disease, HER2 positive disease as well as agnostic breast cancers subtypes were discussed.
Read moreBJMO - volume 13, issue 5, august 2019
T. Vermassen PhD, S. Rottey MD, PhD
From June 1st till June 5th, Chicago was host for the 55th annual ASCO meeting. This report will highlight the most important studies concerning genitourinary cancers presented during the meeting.
Read moreBJMO - volume 13, issue 5, august 2019
Prof B. Neyns MD, PhD
ASCO 2019 featured the presentation of several interesting studies in patients with metastatic melanoma. In addition to this, new data in the (neo)-adjuvant setting were presented.
Read more
Top
